Halozyme Therapeutics (NASDAQ: HALO) executives highlighted what they described as a "significant and value-creating" 2025, pointing to accelerating royalty growth from ENHANZE-enabled products, expansion into additional subcutaneous drug delivery technologies through acquisitions, and a widening pipeline expected to support longer-term revenue durability. 2025 highlights: portfolio expansion and new collaborations On the call, President and CEO Dr.

Halozyme Therapeutics, Inc. (NASDAQ: HALO - Get Free Report)'s stock price dropped 8.7% during trading on Wednesday following a weaker than expected earnings announcement. The company traded as low as $73.00 and last traded at $73.4740. Approximately 2,311,550 shares were traded during mid-day trading, an increase of 17% from the average daily volume of 1,975,592 shares.

HALO swings to Q4 loss on acquisition charge, but revenues surge 52%, fueled by royalties and product sales and top estimates.

Halozyme Therapeutics is entering a powerful earnings inflection, driven by surging royalty revenue and strategic acquisitions expanding its drug delivery platform. FY25 revenue grew 38% to $1.397 billion, with royalty revenue up 52%; recent acquisitions extend IP life and diversify the technology portfolio. 2026 guidance targets $1.71–$1.81 billion in revenue, over 70% EBITDA growth, and nearly 100% EPS growth, highlighting operating leverage and platform scalability.

Halozyme Therapeutics, Inc. (HALO) Q4 2025 Earnings Call Transcript

The headline numbers for Halozyme Therapeutics (HALO) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Halozyme Therapeutics (HALO) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of $2.15. This compares to earnings of $1.26 per share a year ago.

Full Year 2025 Total Revenue Increased 38% YOY to Record $1.397 billion Full Year 2025 Royalty Revenue Increased 52% YOY to Record $868 million Completed Acquisitions of Elektrofi's Hypercon™ Technology and  Surf Bio's Hyperconcentration Technology Reiterating 2026 Financial Guidance Ranges: Total Revenue of $1.710 - $1.810 billion, YOY Growth of 22% - 30% Adjusted EBITDA of $1.125 - $1.205 billion, YOY Growth of 71% - 83%1 Non-GAAP Diluted EPS of $7.75 - $8.25, YOY Growth of 87% - 99%1 SAN DIEGO, Feb. 17, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the full year and fourth quarter ended December 31, 2025, and provided an update on its recent corporate activities. "2025 was a pivotal year for Halozyme as we delivered record total revenue of $1.4 billion, which was the result of continued growth in our ENHANZE business.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Evaluate the expected performance of Halozyme Therapeutics (HALO) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.